Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads by Date

Must reads for theWeek ending March 24, 2019

Study explores third-line trabectedin plus PLD for BRCA1/2 ovarian cancer,

Combo shows promise for endometrial, ovarian cancers,

Rituximab boosts survival in primary CNS lymphoma,

Study: Racial disparities in gyn-onc trial enrollment persist,

What does COMPASS mean for vascular surgeons?,

More must reads

Must reads for theWeek ending March 17, 2019

Financial toxicity may be common in gynecologic cancer patients,

Tumor testing cost-effective for triage to germline testing in HGSOC patients,

Brachytherapy proves beneficial regardless of treatment duration,

ENGOT-OV16/NOVA trial: Analysis shows improved TWiST with niraparib,

Repeat VTE risk heightened in HIV patients,

More must reads

Must reads for theWeek ending March 10, 2019

Coagulation Pathway May Play Role in IBD,

KD025 Produces Durable Responses in Patients with cGVHD,

FDA Expanded Access benefits heavily pretreated patients, especially children,

Model shows nivolumab plus ipilimumab cost effective in mRCC,

Matching clinical, claims data essential for value-based care, Parikh A et al. J Oncol Pract. 2019 Feb 11. doi: 10.1200/JOP.18.00336.
More must reads

Must reads for theWeek ending March 3, 2019

Myeloma therapies raise cardiovascular risks,

SEER data: Abiraterone acetate may up mortality risk in prostate cancer patients with CVD,

Sperm counts largely stable after adjuvant treatment of clinical stage I testicular cancer,

Diet appears to play an important role in response to anti-PD-1 cancer immunotherapy,

Interactive online module improved detection of Barrett’s esophagus neoplasia,

More must reads

Must reads for theWeek ending February 24, 2019

Regimen shows promise as salvage for classical HL,

SABR response rate falls short in early NSCLC,

First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.

President Trump requests $500 million for pediatric cancer, Trump D. State of the Union Address, Feb. 5, 2019.

A shift in Medicare drug coverage may boost costs for patients, Hwang TJ et al. JAMA Int Med. 2019. doi: 10.1001/jamainternmed.2018.6417.
More must reads

Pages